Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,457 shares of the biopharmaceutical company's stock after purchasing an additional 4,457 shares during the period. Regeneron Pharmaceuticals accounts for about 3.2% of Rhenman & Partners Asset Management AB's holdings, making the stock its 5th biggest position. Rhenman & Partners Asset Management AB's holdings in Regeneron Pharmaceuticals were worth $30,956,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Pamalican Asset Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $4,915,000. Intact Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $356,000. Principal Financial Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after acquiring an additional 2,828 shares during the period. Fagan Associates Inc. grew its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Finally, Golden State Equity Partners raised its stake in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 1,272 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have commented on REGN shares. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Regeneron Pharmaceuticals Trading Down 5.9 %

REGN traded down $34.29 during midday trading on Thursday, hitting $542.44. The company's stock had a trading volume of 594,371 shares, compared to its average volume of 976,239. The firm has a market cap of $59.30 billion, a P/E ratio of 14.17, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $665.21 and a two-hundred day moving average price of $762.01.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.